PMID- 26221333
OWN - NLM
STAT- PubMed-not-MEDLINE
DCOM- 20150729
LR  - 20200930
IS  - 1940-5901 (Print)
IS  - 1940-5901 (Electronic)
IS  - 1940-5901 (Linking)
VI  - 8
IP  - 5
DP  - 2015
TI  - Interleukin-34 in rheumatoid arthritis: potential role in clinical therapy.
PG  - 7809-15
AB  - OBJECTIVE: To investigate, whether interleukin (IL)-34 can be used as marker for 
      treatment effectiveness in rheumatoid arthritis (RA). METHODS: Serum samples were 
      collected from 35 healthy participants and 83 patients with RA before as well as 
      4 weeks and 12 weeks after treatment initiation with the tumor necrosis factor alpha 
      (TNF-alpha) inhibitor Etanercept. Related clinical data and hand radiograms of the 
      patients were evaluated and serum IL-34, IL-6, IL-8, TNF-alpha, matrix 
      metalloproteinase-3 (MMP-3) in addition to anti-cyclic citrullinated peptide 
      (CCP) antibody concentrations were measured by ELISA. RESULTS: Serum 
      concentrations of IL-34, IL-6, IL-8, TNF-alpha, MMP-3 and anti-CCP antibodies were 
      markedly elevated in RA patients compared with controls (P<0.001), significantly 
      decreased during treatment and correlated with erythrocyte sedimentation rate 
      (ESR), C-reactive protein (CRP) and RA disease activity (P<0.05). IL-34 
      correlated withIL-6, IL-8, TNF-alpha, MMP-3 and anti-CCP antibodies in RA patients at 
      baseline (P<0.01) and also with IL-8, MMP-3, IL-6, and DAS28 changes during 
      therapy. Patients in stage III of hand X-ray RA scores had higher IL-34 serum 
      concentrations than in stage II (P<0.05). IL-34 level decreased significantly 
      (P<0.01) starting from 4 weeks after therapy initiation. CONCLUSIONS: IL-34 serum 
      concentrations correlated with inflammatory cytokines before and during therapy 
      and were significantly higher in stage III of hand X-ray score patients than in 
      stage II participants. IL-34 might be used both as a biomarker for RA diagnosis 
      and therapy efficiency.
FAU - Zhang, Fangze
AU  - Zhang F
AD  - Department of Rheumatology and Immunology, China-Japan Union Hospital of Jilin 
      University Changchun 130033, China.
FAU - Ding, Rui
AU  - Ding R
AD  - Department of Rheumatology and Immunology, China-Japan Union Hospital of Jilin 
      University Changchun 130033, China.
FAU - Li, Ping
AU  - Li P
AD  - Department of Rheumatology and Immunology, China-Japan Union Hospital of Jilin 
      University Changchun 130033, China.
FAU - Ma, Cuili
AU  - Ma C
AD  - Department of Rheumatology and Immunology, China-Japan Union Hospital of Jilin 
      University Changchun 130033, China.
FAU - Song, Ding
AU  - Song D
AD  - Department of Rheumatology and Immunology, China-Japan Union Hospital of Jilin 
      University Changchun 130033, China.
FAU - Wang, Xuetong
AU  - Wang X
AD  - Department of Rheumatology and Immunology, China-Japan Union Hospital of Jilin 
      University Changchun 130033, China.
FAU - Ma, Tianjiao
AU  - Ma T
AD  - Department of Rheumatology and Immunology, China-Japan Union Hospital of Jilin 
      University Changchun 130033, China.
FAU - Bi, Liqi
AU  - Bi L
AD  - Department of Rheumatology and Immunology, China-Japan Union Hospital of Jilin 
      University Changchun 130033, China.
LA  - eng
PT  - Journal Article
DEP - 20150515
PL  - United States
TA  - Int J Clin Exp Med
JT  - International journal of clinical and experimental medicine
JID - 101471010
PMC - PMC4509278
OTO - NOTNLM
OT  - IL-34
OT  - IL-6
OT  - IL-8
OT  - MMP-3
OT  - Rheumatoid arthritis
OT  - TNF-alpha
EDAT- 2015/07/30 06:00
MHDA- 2015/07/30 06:01
PMCR- 2015/05/15
CRDT- 2015/07/30 06:00
PHST- 2015/01/06 00:00 [received]
PHST- 2015/04/28 00:00 [accepted]
PHST- 2015/07/30 06:00 [entrez]
PHST- 2015/07/30 06:00 [pubmed]
PHST- 2015/07/30 06:01 [medline]
PHST- 2015/05/15 00:00 [pmc-release]
PST - epublish
SO  - Int J Clin Exp Med. 2015 May 15;8(5):7809-15. eCollection 2015.